261 related articles for article (PubMed ID: 34148293)
1. Intrinsic drug potential of oxazolo[5,4-d]pyrimidines and oxazolo[4,5-d]pyrimidines.
Zhirnov VV; Velihina YS; Mitiukhin OP; Brovarets VS
Chem Biol Drug Des; 2021 Oct; 98(4):561-581. PubMed ID: 34148293
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 5-(or 6)-benzoxazoles and oxazolo[4,5-b]pyridines as novel candidate antitumor agents targeting hTopo IIα.
Karatas E; Foto E; Ertan-Bolelli T; Yalcin-Ozkat G; Yilmaz S; Ataei S; Zilifdar F; Yildiz I
Bioorg Chem; 2021 Jul; 112():104913. PubMed ID: 33945950
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1.
Ye F; Wang Y; Nian S; Wang Y; Chen D; Yu S; Wang S
J Enzyme Inhib Med Chem; 2015 Dec; 30(6):961-6. PubMed ID: 25683078
[TBL] [Abstract][Full Text] [Related]
4. Diarylureas and Diarylamides with Oxazolo[5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors.
Deng YH; Liu JP; Cheng YJ; Liu Y; Sun LP
Chem Biodivers; 2016 Sep; 13(9):1230-1239. PubMed ID: 27448711
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Activity of New 7-Amino-oxazolo[5,4-
Sochacka-Ćwikła A; Regiec A; Zimecki M; Artym J; Zaczyńska E; Kocięba M; Kochanowska I; Bryndal I; Pyra A; Mączyński M
Molecules; 2020 Aug; 25(15):. PubMed ID: 32759841
[TBL] [Abstract][Full Text] [Related]
6. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
7. Development of novel oxazolo[5,4-d]pyrimidines as competitive CB
Tuo W; Bollier M; Leleu-Chavain N; Lemaire L; Barczyk A; Dezitter X; Klupsch F; Szczepanski F; Spencer J; Chavatte P; Millet R
Eur J Med Chem; 2018 Feb; 146():68-78. PubMed ID: 29360044
[TBL] [Abstract][Full Text] [Related]
8. New Oxazolo[5,4-
Sochacka-Ćwikła A; Mączyński M; Czyżnikowska Ż; Wiatrak B; Jęśkowiak I; Czerski A; Regiec A
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232997
[TBL] [Abstract][Full Text] [Related]
9. Application and SARs of Pyrazolo[1,5-a]pyrimidine as Antitumor Agents Scaffold.
Zhang Y; Wen D; Shen J; Tian L; Zhu Y; Zhang J; Zhao L; Ding S; Liu J; Chen Y
Curr Top Med Chem; 2023; 23(12):1043-1064. PubMed ID: 36852801
[TBL] [Abstract][Full Text] [Related]
10. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Evaluation of Some 5-Arylthieno[2,3-d]pyrimidines as Potential Anti-cancer Agents.
El-Ansary AK; Kamal AM; Al-Ghorafi MA
Chem Pharm Bull (Tokyo); 2016; 64(8):1172-80. PubMed ID: 27477657
[TBL] [Abstract][Full Text] [Related]
13. Fused and Substituted Pyrimidine Derivatives as Profound Anti-Cancer Agents.
Abbas N; Matada GSP; Dhiwar PS; Patel S; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(7):861-893. PubMed ID: 32698738
[TBL] [Abstract][Full Text] [Related]
14. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
15. Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.
Ghith A; Ismail NSM; Youssef K; Abouzid KAM
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 29027246
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
[TBL] [Abstract][Full Text] [Related]
17. Expanding the scope of fused pyrimidines as kinase inhibitor scaffolds: synthesis and modification of pyrido[3,4-d]pyrimidines.
Innocenti P; Woodward H; O'Fee L; Hoelder S
Org Biomol Chem; 2015 Jan; 13(3):893-904. PubMed ID: 25407826
[TBL] [Abstract][Full Text] [Related]
18. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
